Approach to medical therapy in perianal Crohn’s disease

Table 1 Table of trials evaluating ideal cut off value for infliximab and adalimumab concentrations

Ref.	Population (adults or children)	Number	Study design	Follow up or time on therapy	Outcomes	Median level	Median level
Trial: Infliximab
Plevris et al[43]	Adult	29	Retrospective single center cross sectional	2.6 yr	Fistula healing; Fistula closure	8.1; 8.2	3.2; 3.2
Strik et al[40]	Adult	47	Retrospective single centercross sectional	3.5 yr	Fistula closure	6.0	2.3
Davidov et al[44]	Adult	36	Retrospective observational two centers	Week 2; Week 6; Week 14	Decrease or cessation of fistula drainage at week 14	20; 13.3; 4.1	5.6; 2.55; 0.14
Zhu et al[69]	Adult	157	Retrospective single center	Week 30; Week 78; Week 116	Radiological remission (absence of high-signal tracks on fat-saturated T2-weighted sequences)	3.5; 2.85; 2.84	1.9; 1.63; 0.7
El-Matary et al[42]	Pediatric	85	Prospective observational 12 centers	Week 14	Clinical fistula healing at week 24	12.7	5.4
Yarur et al[39]	Adult	117	Retrospective, cross sectional, 2 centers	29 wk	Fistula healing	15.8	4.4
Trial: Adalimumab
Plevris et al[43]	Adult	35	Retrospective single center cross sectional	1.7 yr	Fistula healing; Fistula closure	14.8; 12.6	5.7; 2.7
Strik et al[40]	Adult	19	Retrospective single center cross sectional	3.5 yr	Fistula closure	7.4	4.8
Ruemmele et al[41]	Pediatric	36	Randomized control trial	Week 16; Week 52	Clinical fistula closure	7.4; 7.5	6.4; 5.6